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Comparative efficacy of delafloxacin 
for complicated and acute bacterial skin 
and skin structure infections: results 
from a network meta-analysis
Ioanna Vlachaki1, Matteo Vacchelli2, Daniela Zinzi1, Edel Falla3 , Yilin Jiang4, Theo Mantopoulos5* and 
Dilip Nathwani6 
Abstract 
Background: Delafloxacin is a novel fluoroquinolone with broad antibacterial activity against pathogens causing 
acute bacterial skin and skin structure infections (ABSSSI). This network meta-analysis (NMA) was conducted to evalu-
ate the relative efficacy of delafloxacin versus other comparators used for managing patients with ABSSSI.
Methods: A systematic literature review was conducted to identify randomised controlled trials (RCTs) evaluating 
adults (≥ 18 years) with ABSSSI, complicated SSSI (cSSSI), complicated skin and soft tissue infections (cSSTI) or severe 
cellulitis with pathogen of gram-positive, gram-negative, or mixed aetiology. OVID  MEDLINE®, Embase, Epub Ahead 
of Print, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews were searched 
from inception through 12 April 2019. A feasibility assessment was conducted, followed by an NMA, which was run in 
a Bayesian framework. The interventions included in the NMA encompassed monotherapy or combination therapies 
of amoxicillin/clavulanate, ampicillin/sulbactam, ceftaroline, ceftobiprole, dalbavancin, daptomycin, delafloxacin, 
fusidic acid, iclaprim, linezolid, omadacycline, oxacillin + dicloxacillin, standard therapy, tedizolid, telavancin, tigecy-
cline, vancomycin, vancomycin + aztreonam and vancomycin + linezolid.
Results: A feasibility assessment was performed and evidence networks were established for composite clinical 
response (n = 34 studies), early clinical response (n = 16 studies) and microbiological response (n = 14 studies) in 
the overall study population, composite clinical response (n = 4 studies) in obese subpopulation and for composite 
clinical response (n = 18 studies) and microbiological response (n = 14 studies) in patients with methicillin-resistant 
Staphylococcus aureus (MRSA) infection. Delafloxacin performed significantly better than fusidic acid, iclaprim, vanco-
mycin, and ceftobiprole for composite clinical response. Delafloxacin was comparable to dalbavancin, daptomycin, 
fusidic acid, iclaprim, linezolid, omadacycline, tedizolid, vancomycin, vancomycin + aztreonam and vancomycin + lin-
ezolid in the analysis of early clinical response, whereas for microbiological response, delafloxacin was comparable to 
all interventions. In the obese subpopulation, the results favoured delafloxacin in comparison to vancomycin, whilst 
the results were comparable with other interventions among the MRSA subpopulation.
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permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
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regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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Introduction
Complicated skin and soft tissue infections (cSSTI), or 
complicated skin and skin structure infections (cSSSI), 
represent a severe form of skin infections involving the 
skin and deeper soft tissues [1]. cSSSI have been associ-
ated with increasing morbidity, mortality and healthcare 
costs in recent decades [1, 2]. The overall incidence of 
SSTI in the United States (US) increased 40% from 2.4 
million in 2000 to 3.3 million in 2012 [3]. In 2013, the US 
Food and Drug Administration (FDA) distinctly defined 
a subset of severe skin infections as acute bacterial skin 
and skin structure infections (ABSSSI) to facilitate the 
clinical development of drugs and evaluate efficacy of 
novel antibiotics through quantifiable variables such as 
lesion size and systemic signs of infections [4, 5]. Accord-
ing to the US FDA, ABSSSI include cellulitis, erysipelas, 
wound infections or major cutaneous abscesses with a 
minimum lesion surface area of 75  cm2, measured by ery-
thema, oedema or induration [5, 6]. ABSSSI are caused 
most commonly by gram-positive bacteria such as Strep-
tococcus pyogenes and Staphylococcus aureus, including 
methicillin-resistant S. aureus (MRSA) strains [5, 7, 8]. In 
2018, epidemiological data from 30 participating coun-
tries in the European Antimicrobial Resistance Surveil-
lance (EARS) network and European Centre for Disease 
prevention and Control (ECDC) estimated that MRSA 
accounted for 16.4% of all S. aureus isolates, with signifi-
cant differences in national MRSA percentages ranging 
from 0% in Iceland to 43% in Romania [9]. The Centre for 
Disease Control and Prevention has recognised MRSA 
as a serious health threat to humans with an estimated 
323,700 hospitalisations and 10,600 deaths across the US 
in 2017 [10]. Despite a decline in MRSA- related hospi-
talisations since 2005, MRSA accounts for significant 
morbidity and mortality in the US [11, 12].
Treatment approaches for ABSSSI according to the 
Infectious Disease Society of America (IDSA) practice 
guidelines include surgical drainage or debridement 
when appropriate, culture and susceptibility testing and 
appropriate empiric antibiotic therapy [6]. The increas-
ing prevalence of MRSA in the past decade has altered 
the therapeutic approach to ABSSSI [6, 13]. The IDSA 
guidelines recommend vancomycin as the first-line agent 
for MRSA ABSSSI [6]. However, higher vancomycin 
doses often used to treat MRSA infections may lead to 
serious complications such as nephrotoxicity, ototoxicity 
and hypersensitivity reactions, which can be associated 
with prolonged hospitalisation and increased healthcare 
costs [14–17]. Other recommended antibiotics for MRSA 
include linezolid, daptomycin, ceftaroline and telavancin 
[6]. However, these antibiotics are ineffective against 
gram-negative bacteria, except ceftaroline which is effec-
tive against some gram-negative pathogens, exclud-
ing Pseudomonas aeruginosa and multi-drug resistant 
gram-negative bacteria [18]. Nafcillin, cefazolin and 
clindamycin may also be considered for ABSSSI caused 
by methicillin-sensitive S. aureus (MSSA) [6, 19]. The 
antimicrobial activity of recently approved antibiotics for 
the treatment of ABSSSI, namely, dalbavancin [20], orita-
vancin [21] and tedizolid [22] are also limited to strains 
of gram-positive pathogens, including MRSA. The global 
emergence of MRSA strains and other resistant patho-
gens in recent years has imposed a considerable chal-
lenge to its management, compelling a drive to develop 
safe and effective antibiotics for the treatment of ABSSSI, 
including MRSA-related infections [9, 23].
Obese patients with ABSSSIs are at a higher risk of 
treatment failure and have demonstrated slow recovery 
[24, 25] According to the World Health Organisation, 
globally 39% adults (≥ 18 years) were overweight, whilst 
about 13% of the world’s adult population was obese in 
2016, making it a clinically important subpopulation of 
interest [26].
Delafloxacin, a novel fluoroquinolone with activ-
ity against a diverse range of gram-positive (S. 
aureus,[including MRSA] and Streptococcus pyogenes) 
and gram-negative bacteria (Pseudomonas aerugi-
nosa, Escherichia coli and Klebsiella pneumoniae), was 
approved by the US FDA for ABSSSI in 2017 and by 
the European Medicines Agency in 2019 [27–29]. Dela-
floxacin is available in oral and intravenous (IV) forms, 
at a recommended dose of 300  mg IV or 450  mg orally 
once every 12  h [28]. The clinical efficacy of delafloxa-
cin was explored in a large developmental programme 
that included two phase III clinical trials, demonstrating 
that delafloxacin was non-inferior to the combination of 
vancomycin plus aztreonam for the treatment of ABSSSI 
[30, 31]. Whilst the efficacy of delafloxacin in ABSSSI 
was assessed in comparison to vancomycin plus aztre-
onam, there are no randomised controlled trials (RCTs) 
Conclusions: Delafloxacin is a promising new antibiotic for ABSSSI demonstrating greater improvement (composite 
clinical response) compared to ceftobiprole, fusidic acid, iclaprim, telavancin and vancomycin and comparable effec-
tiveness versus standard of care for all outcomes considered in the study.
Keywords: Acute bacterial skin and skin structure infections, Methicillin-resistant Staphylococcus aureus, Delafloxacin, 
Network meta-analysis
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available to assess the comparative effectiveness for other 
comparators used for the management of ABSSSI.
Two previous systematic literature reviews (SLRs) 
and meta-analyses investigating the safety and efficacy 
of delafloxacin for the treatment of ABSSSI in adult 
patients demonstrated similar clinical cure rates of dela-
floxacin versus comparators in the treatment of ABSSSI 
and MRSA ABSSSI’s [32, 33]. However, these studies 
included publications with ABSSSI populations only and 
as such, evaluated overall clinical cure or microbiological 
response for limited number of interventions (i.e. ceftobi-
prole, linezolid, tigecycline, and vancomycin/aztreonam) 
among the current standard of care for the treatment of 
ABSSSI. This network meta-analysis (NMA) aims to add 
to the existing knowledge on the performance of dela-
floxacin in terms of composite clinical response, micro-
biological response and early response versus the current 
standard of care, including obese patients (body mass 
index [BMI] ≥ 30 kg/m2) and patients with MRSA.
Methods
An SLR was conducted in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions Ver-
sion 5.1.0 to identify the clinical evidence from RCTs for 
delafloxacin versus standard of care in adult patients with 
ABSSSI, cSSSI, cSSTI or severe cellulitis [34].
Data sources and search strategy
OVID  MEDLINE®, Embase, Epub Ahead of Print (In-
process & other non-indexed citations), and Cochrane 
Central Register of Controlled Trials and Cochrane Data-
base of Systematic Reviews were searched for relevant 
RCTs with a prespecified search strategy. Additional 
searches were performed in the conference proceedings 
of European Society of Clinical Microbiology and Infec-
tious Diseases, Infectious Diseases Week and World 
Antimicrobial Resistance Congress Europe from 2017 to 
2019. The searches executed in the SLR were based on 
pre-defined patient population, intervention, compara-
tors, outcome measures and study design criteria (Addi-
tional file 1: Appendix A). RCTs involving adult patients 
with ABSSSI, cSSSI, cSSTI or severe cellulitis, were 
selected for inclusion. The databases were systematically 
searched from inception through 12 April 2019.
Study selection and identification
All identified records were exported to  Microsoft® Excel 
after removing duplicates in a reference management 
software. Abstract screening was conducted based on 
pre-defined eligibility criteria. Publications with uncer-
tainty were reviewed by an independent second reviewer, 
and any disagreement was resolved either through “rec-
onciliation” (discussion between the two reviewers) or 
through “arbitration” with a third independent reviewer 
where “majority view” determined the inclusion/exclu-
sion. All records included at the end of this stage were 
retained for full text review, followed by data extraction 
and quality appraisal. A descriptive quality assessment 
of the included RCTs was performed using the Cochrane 
checklist as per the National Institute for Health and 
Care Excellence (NICE) technical support document 
(TSD) 2 for NMA of RCTs of RCTs (Additional file  1: 
Appendix B) [35, 36].
Feasibility assessment
The feasibility of conducting an NMA was examined by 
first assessing if a connected network of evidence could 
be established for each outcome of interest, based on 
the clinical evidence identified from the SLR. The stud-
ies included in the connected networks were further 
assessed for the presence and extent of between-study 
heterogeneity. To assess the comparability of study 
populations, a comparison of patients’ baseline charac-
teristics (i.e. age, gender, BMI, race, MRSA/MSSA popu-
lation, treatment duration, polymicrobial infections, and 
comorbidities) was conducted. Study design characteris-
tics for all included RCTs (e.g. cross-over or open label) 
were assessed to identify potential sources of bias that 




Due to the heterogeneity of outcome definitions, studies 
with similar outcome definitions at similar timepoints 
were grouped together, and any assumptions were vali-
dated by two clinical experts (Additional file 1: Appendix 
D).
The RCTs reporting clinical cure or success outcomes 
at the end of therapy, test of cure (TOC), post-therapy 
evaluation or follow-up were considered for the out-
come ‘composite clinical response’ in the analysis. Wher-
ever a study reported both clinical cure and clinical 
success, clinical success was considered as the efficacy 
outcome for analysis. ‘Early response’ was determined 
as either ≥ 20% lesion size reduction or early clinical 
response at 48–72 h. When a study reported both ≥ 20% 
lesion size reduction and early clinical response, ≥ 20% 
lesion size reduction was considered as the efficacy out-
come for analysis. Documented eradication or presumed 
eradication of baseline pathogens was considered as 
‘microbiological response’.
Assumptions on the study design and patient population
The potential bias due to any heterogeneity in study 
design and patient characteristics were also investigated 
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and validated by a clinical expert. Populations and study 
design were deemed to be comparable and unlikely to 
have an impact on the NMA results. Variation in anti-
biotic dosing across trials was observed for delafloxa-
cin, telavancin, iclaprim, vancomycin, omadacycline and 
dalbavancin, however as per the clinical expert opinion 
the variation in dosing schedules between studies was 
unlikely to influence the NMA results (Additional file 1: 
Appendix D). Doses were therefore pooled in the analy-
sis after consultation with two clinical experts. For each 
study, outcome data from the ITT population were used 
in the analysis, whereas in the absence of the ITT popula-
tion for a particular study, data from the population clos-
est to the ITT was used instead (e.g., modified ITT). The 
analysis population from each RCT is presented in sup-
plementary material Additional file 1: Appendix D.
Network meta‑analysis
Bayesian NMA models were used to synthesise the 
results of included studies as per the NICE guidance 
[36]. The analyses were based on a burn-in of 80,000 
iterations and a further sample of 20,000 iterations until 
convergence was achieved. The Monte Carlo error was 
captured, which reflects both the number of simulations 
and the degree of autocorrelation. This should be no 
more than 5% of the posterior standard deviation of the 
parameters of interest. Finally, visual inspection of trace/
density plots was carried out. As suggested by the NICE 
Decision Support Unit TSD 2 a normal distribution 
with zero mean and variance equal to  104 was used for 
treatment effects and a uniform distribution with range 
zero to 5 for the between-trial standard deviation [36]. 
Vague (flat/uninformative) priors were used for all cal-
culations. The analyses were conducted using JAGS (ver-
sion 4.3.0) with RStudio (version 3.5.1) as the front end. 
The analyses consisted of binary outcomes. A binomial 
model with a logit link function was employed for all out-
comes based on NICE guidance [36]. Both fixed effects 
and random effects models were run to test the model 
fit and assess heterogeneity. Given that the fixed effect 
models provided better fit than the random effect mod-
els in all analyses and the limited information to estimate 
between-study variance in the random effect models in 
some analyses, only results for the fixed effects models 
are discussed in the main body of the paper. Model fit 
statistics and results from the random effect models are 
presented in Additional file 1: Appendix E and Appendix 
F, respectively. Inconsistency, that is, the lack of agree-
ment between direct and indirect evidence in an NMA, 
was assessed for each loop in the networks. Inconsistency 
was assessed by the inconsistency model, as described in 
the NICE Decision Support Unit TSD 4 [37].
For each outcome, an odds ratio (OR) was used to 
reflect the relative treatment effects between interven-
tions. Forest plots were presented using the posterior 
median of OR for each pairwise treatment compari-
son. The 2.5th and 97.5th percentiles to capture the 95% 
credible interval (CrI) of corresponding ORs were also 
provided along with the posterior median. For all out-
comes a median OR > 1 indicates favourable results for 
delafloxacin.
Results
The SLR search identified 2212 studies after removing 
duplicates. Following the abstract screening, 1985 studies 
were excluded as they did not meet the eligibility criteria 
and 227 publications were assessed for full text review. 
Out of these, 48 primary studies from 79 publications 
were considered for the NMA feasibility assessment. 
Nine primary studies were excluded as they did not form 
a connection in the networks. Two oritavancin phase III 
RCTs were excluded from the NMA, as the study pop-
ulation in these two studies included a lower propor-
tion of elderly and obese patients than the pivotal RCT 
on delafloxacin [38, 39]. Overall, 37 primary RCTs were 
included in the NMA following full text screening and 
feasibility assessment (Fig.  1). The results of the quality 
assessment for included RCTs suggested an overall low or 
moderate risk of bias. A high risk of bias was observed 
in terms of blinding for seven open label RCTs [40–46]. 
Evidence networks were established for the overall study 
population (outcomes: composite clinical response, early 
clinical response, and microbiological response), patients 
with obesity (outcome: composite clinical response) 
and patients with MRSA (outcomes: composite clinical 
response and microbiological response). The evidence 
network for patients with obesity (outcomes: early clini-
cal response and microbiological response) and patients 
with MRSA (outcome: early clinical response) could 
not be established due to the limited number of studies 
reporting outcomes for these subgroups.
An assessment of the degree of between-study het-
erogeneity was conducted and was validated with two 
clinical experts by examining differences across stud-
ies eligible for inclusion in the NMA. Potential effect 
modifiers were generally similar across the included 
studies, and where variability across studies was noted 
(e.g., proportion of MSSA patients, proportion of 
MRSA patients, mean treatment duration, propor-
tion of patients with comorbidities), they were fur-
ther discussed and validated with clinical experts. The 
potential sources of heterogeneity are presented in 
Additional file 1: Appendix C. The outcome of the fea-
sibility was that the studies were generally comparable 
with a low risk of bias from treatment effect modifiers. 
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Based on feedback from the two clinical experts, and 
given that no considerable evidence of heterogene-
ity was found (as evidenced from the better fit of the 
fixed effect models over the random effect models), two 
sensitivity analyses were also conducted to assess the 
impact of the populations considered and three ‘outlier 
studies’ identified. The first sensitivity analysis included 
only studies which reported outcomes in the ITT (or 
mITT) population, and the second removed three stud-
ies (Wilcox et al. 2009 [42], Sharpe et al. 2005 [46] and 
Pushker et al. [47]) from the evidence networks, which 
were deemed to potentially introduce bias due to their 
small sample sizes and differences in baseline patient 
characteristics compared to the other included studies.
Inconsistency was tested in the evidence networks 
for “all patients: composite clinical response” and “all 
patients: microbiological response”, as these two net-
works had closed loops (between delafloxacin, vancomy-
cin, vancomycin + aztreonam, ceftaroline and tigecycline 
in the first network and between delafloxacin, vanco-
mycin, vancomycin + aztreonam, ceftaroline in the sec-
ond). No evidence of inconsistency in either network was 
found. Results from the inconsistency assessment are 
presented in Additional file 1: Appendix G.
Across the 37 RCTs in the evidence networks, efficacy 
outcomes were included from 18 interventions, of which 
vancomycin and linezolid were the most common inter-
ventions (Additional file  1: Appendix D). Two studies 
Fig. 1 PRISMA flow chart. NMA network metanalysis, SLR systematic literature review
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considered the use of either an anti-staphylococcal peni-
cillin (including activity against MRSA) or vancomycin as 
‘Standard therapy’ (ST) [48, 49].
All patients
Composite clinical response
The network of evidence for composite clinical response 
consisted of 34 studies, reporting estimates for 18 inter-
ventions (Fig. 2). The results were in favour of delafloxa-
cin in comparison to ceftobiprole, fusidic acid, iclaprim 
and vancomycin. Results for amoxicillin/clavulanate, 
ampicillin/sulbactam, ceftaroline fosamil, dalbavancin, 
daptomycin, delafloxacin, linezolid, omadacycline, oxacil-
lin + dicloxacillin, ST (i.e. anti-staphylococcal penicillin 
or vancomycin), tedizolid, telavancin, tigecycline, van-
comycin + aztreonam and vancomycin + linezolid were 
comparable to delafloxacin. The forest plot of median 
ORs and associated 95% CrIs for delafloxacin versus all 
comparators is presented in Fig. 3.
Early clinical response
In terms of early clinical response, delafloxacin was 
comparable to dalbavancin, daptomycin, fusidic acid, 
iclaprim, linezolid, omadacycline, tedizolid, vancomycin, 
vancomycin + aztreonam and vancomycin + linezolid. 
The network of evidence and the forest plot of median 
ORs and associated 95% CrIs for early clinical response 
are presented in Additional file 1: Appendix H and Fig. 4, 
respectively.
Microbiological response
For microbiological response, delafloxacin was compara-
ble to all interventions i.e. ampicillin/sulbactam, amoxi-
cillin/clavulanate, ceftaroline, ceftobiprole, dalbavancin, 
linezolid, oxacillin + dicloxacillin, tigecycline, vancomy-
cin + aztreonam, and vancomycin. The median ORs and 
associated 95% CrIs for microbiological response are pre-
sented in Fig. 5 and the network of evidence is presented 
in Additional file 1: Appendix I.
Obese patients (BMI ≥ 30 kg/m2)
Composite clinical response
Results for composite clinical response in obese 
patients favoured delafloxacin in comparison to vanco-
mycin. However, the results for delafloxacin, linezolid 
and vancomycin + aztreonam were comparable. The 
Fig. 2 Network of evidence for all patients: composite clinical response. ASAC ampicillin/sulbactam or amoxicillin/clavulanate, CEF ceftaroline, 
CEFT ceftobiprole, DAL dalbavancin, DAP daptomycin, DEL delafloxacin, FUS fusidic acid, ICL iclaprim, LIN linezolid, OD oxacillin + dicloxacillin, OMA 
omadacycline, ST standard therapy, TED tedizolid, TEL telavancin, TIG tigecycline, VA vancomycin + aztreonam, VAN vancomycin, VL vancomycin + 
linezolid
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forest plot of median ORs and associated 95% CrIs in 
obese patients is presented in Fig. 6, and the network of 
evidence is presented in Additional file 1: Appendix J.
Additional subgroup: patients with MRSA infection
The network of evidence for patients with MRSA infec-
tion consisted of 18 studies, reporting estimates for 
ten interventions. For composite clinical response, 
Fig. 3 Forest plot for all patients: composite clinical response. ASAC ampicillin/sulbactam or amoxicillin/clavulanate, CEF ceftaroline, CEFT 
ceftobiprole, DAL dalbavancin, DAP daptomycin, DEL delafloxacin, FUS fusidic acid, ICL iclaprim, LIN linezolid, OD oxacillin + dicloxacillin, OMA 
omadacycline, ST standard therapy, TED tedizolid, TEL telavancin, TIG tigecycline, VA vancomycin + aztreonam, VAN vancomycin, VL vancomycin + 
linezolid
Fig. 4 Forest plot for all patients: early clinical response. DAL dalbavancin, DAP daptomycin, DEL delafloxacin, FUS fusidic acid, ICL iclaprim, LIN 
linezolid, OMA omadacycline, TED tedizolid, VA vancomycin + aztreonam, VAN vancomycin, VL vancomycin + linezolid
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delafloxacin was found to be comparable to all inter-
ventions in the network, namely, ampicillin/sulbactam, 
amoxicillin/clavulanate, ceftobiprole, ceftaroline, lin-
ezolid, omadacycline, tigecycline, vancomycin + aztre-
onam and vancomycin (Additional file  1: Appendix K). 
Similarly, for microbiological response, delafloxacin was 
found to be comparable to ceftaroline, dalbavancin, line-
zolid, tedizolid, tigecycline, vancomycin + aztreonam and 
vancomycin (Additional file 1: Appendix L).
Sensitivity analyses
Sensitivity analyses for ITT/mITT population
Evidence networks were established for the overall popu-
lation for composite clinical response and early clinical 
response. Delafloxacin was superior in terms of com-
posite clinical response in comparisons with fusidic 
acid, iclaprim, vancomycin, and ceftobiprole, whilst with 
other active comparators results were comparable with 
delafloxacin. In early clinical response the results were 
Fig. 5 Forest plot for all patients: microbiological response. ASAC ampicillin/sulbactam or amoxicillin/clavulanate, CEF ceftaroline fosamil, CEFT 
ceftobiprole, DAL dalbavancin, DEL delafloxacin, LIN linezolid, OD oxacillin + dicloxacillin, TIG tigecycline, VA vancomycin + aztreonam, VAN 
vancomycin
Fig. 6 Forest plot for obese subpopulation: composite clinical response. DEL delafloxacin, Lin linezolid, VA vancomycin + aztreonam, VAN 
vancomycin
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comparable for delafloxacin versus fusidic acid, vanco-
mycin, iclaprim, omadacycline, linezolid, tedizolid, and 
vancomycin + aztreonam.
Sensitivity analyses after removing outlier studies
Evidence networks were established for the overall 
population for composite clinical response and micro-
biological response. For composite clinical response, in 
comparisons of delafloxacin with fusidic acid, iclaprim, 
vancomycin, ceftobiprole, and telavancin, the results 
favoured delafloxacin. For the comparisons of dela-
floxacin with the remaining treatments, the results were 
comparable between delafloxacin and the comparator 
treatments.
For microbiological response, the results were compa-
rable for delafloxacin versus ampicillin + sulbactam or 
amoxycillin + clavulanate, ceftobiprole, dalbavancin, lin-
ezolid, oxacillin + dicloxacillin, tigecycline, vancomycin, 
ceftaroline and vancomycin + aztreonam.
Discussion
Delafloxacin is a fluoroquinolone with broad spec-
trum activity against gram-positive pathogens, includ-
ing MRSA and many gram-negative pathogens [30, 50]. 
This NMA included RCTs involving adult patients with 
ABSSSI, cSSSI, cSSTI or severe cellulitis and compre-
hensively evaluated the relative clinical efficacy of dela-
floxacin versus interventions used to treat patients with 
complicated and ABSSSI. In comparison to previously 
published NMAs, this NMA included a broader range of 
infections such as ABSSSI, cSSSIs, cSSTI or severe cellu-
litis, together with a wider array of interventions [32, 33].
The NMA found that, for composite clinical response 
in the overall patient population, the results were in 
favour of delafloxacin when compared to ceftobiprole, 
fusidic acid, iclaprim, and vancomycin. For early clinical 
response, the results were comparable for delafloxacin 
versus dalbavancin, daptomycin, fusidic acid, iclaprim, 
linezolid, omadacycline, tedizolid, vancomycin, van-
comycin + aztreonam and vancomycin + linezolid. For 
microbiological response, delafloxacin showed compa-
rable effectiveness with ampicillin/sulbactam, amoxicil-
lin/clavulanate, ceftaroline, ceftobiprole, dalbavancin, 
linezolid, oxacillin + dicloxacillin, tigecycline, vancomy-
cin + aztreonam, and vancomycin. The relative clinical 
efficacy of delafloxacin versus other treatments in obese 
patients demonstrated consistency with the results of 
composite clinical response in the overall population, as 
delafloxacin showed greater improvement in compari-
son to vancomycin, and comparable results with linezolid 
and vancomycin + aztreonam. Furthermore, delafloxacin 
showed comparable results with other included interven-
tions in terms of composite clinical and microbiological 
response for MRSA patients. The sensitivity analysis 
including only trials reporting outcomes for the ITT/
mITT populations and removing the three outlier studies 
identified by clinical experts were comparable to the base 
case analysis.
Across all analysed populations, particularly for the 
MRSA subpopulation, median OR estimates for several 
treatment comparisons were associated with consider-
able uncertainty, depicted by wide CrIs. This uncertainty 
can be attributed to the availability of data from a lim-
ited number of studies and heterogeneity in study popu-
lations. Therefore, robust conclusions cannot be derived 
for the MRSA subgroup analysis. It should be noted that 
as majority of the identified studies were not carried 
out exclusively in the MRSA population, these studies 
were not specifically designed or powered to detect dif-
ferences in the subgroups. Furthermore, the proportion 
of patients with MRSA also varied across RCTs, which 
reflects the inherent heterogeneity between the included 
trials.
Our findings are consistent with a previous NMA 
involving four RCTs by Lan et al., in which delafloxacin 
exhibited clinical cure rate similar to other comparator 
drugs (OR: 1.05; 95% CI: 0.87 to 1.27;  I2 = 16%) in the 
treatment of ABSSSI [32]. Although, Lan et al. included 
an adult population with ABSSSI that was limited to 
delafloxacin RCTs, thereby comparing delafloxacin to 
just four comparators i.e. tigecycline, vancomycin, lin-
ezolid and vancomycin + aztreonam [32]. In another 
NMA which included ten RCTs, the indirect comparison 
of delafloxacin showed similar efficacy in terms of clini-
cal cure with ceftaroline (OR: 0.82; 95% CrI: 0.39 to 1.8), 
ceftobiprole (OR: 0.79; 95% CrI: 0.32 to 1.9) and tigecy-
cline (OR: 1.0: 95% CrI: 0.45 to 2.2) [33]. However, the 
analysis was restricted to the MRSA ABSSSI population 
and compared the efficacy of delafloxacin with just cef-
taroline, ceftobiprole and tigecycline [33].
The present NMA encompassed 37 RCTs which 
included adult patients with a wide range of severe skin 
and skin structure infections. It evaluated the compara-
tive effectiveness of delafloxacin versus 18 interventions 
in terms of composite clinical response, early clinical 
response and microbiological response. This NMA also 
evaluated the efficacy of delafloxacin with relevant com-
parators for obese patients, which to our knowledge has 
not been evaluated in previously published NMAs [32, 
33]. In the present NMA, an assessment of the risk of 
bias was undertaken for each identified RCT and the var-
iability across studies was validated by the clinical expert.
This study is subject to the limitations inherent to all 
NMAs in terms of heterogeneity of included studies [51]. 
The included RCTs were conducted in populations that 
were categorised by different definitions of infections 
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(ABSSSI, cSSSI, cSSTI, severe cellulitis) and outcomes. 
This could lead to potential bias in the results. However, 
the assessment of inconsistency in the NMA did not sug-
gest any discrepancy in the evidence. In addition, the 
studies included in the NMA were published over a time 
span extending two decades (2000–2019). A number of 
the included studies were conducted before the publica-
tion of the FDA guidance for the design of RCTs to evalu-
ate drugs for ABSSSI [5], justifying the variability in the 
definition of infections. The RCTs assessing ceftaroline 
[52–54] and one of the RCTs assessing delafloxacin [55] 
considered patients with cSSSI whereas three RCTs for 
delafloxacin included patients with ABSSSI [30, 31, 56]. 
Moreover, different dosing regimens were used in RCTs 
assessing ceftaroline, dalbavancin, daptomycin, delafloxa-
cin, linezolid, omadacycline, and telavancin. To facilitate 
the NMA, different doses of treatments were pooled for 
each study. However, the clinical expert validated that the 
treatment doses and infection subtypes across RCTs were 
comparable, therefore, these differences are unlikely to 
introduce bias in the results.
This study provides substantial indirect evidence for 
the comparative efficacy of delafloxacin versus a broad 
range of comparators for the management of ABSSSI. 
Further research is warranted for the comparative effi-
cacy of delafloxacin involving RCTs powered to detect 
differences in populations with obesity and MRSA 
infections.
Conclusion
The results of this NMA substantiate that delafloxacin 
is an effective new antibiotic for ABSSSI. Delafloxacin 
demonstrated improved composite clinical response ver-
sus ceftobiprole, fusidic acid, iclaprim and vancomycin 
in base case analysis, and with telavancin in the scenario 
analysis. For the remaining comparators in composite 
clinical response, in addition to all interventions included 
in the early response and microbiological response anal-
ysis, delafloxacin was equivalent. The results favoured 
delafloxacin in comparison to vancomycin for compos-
ite clinical response in obese patients. Finally, the NMA 
showed that delafloxacin has comparable efficacy to all 
interventions in the MRSA subgroup. Delafloxacin, with 
a broad spectrum activity against MRSA and gram-neg-
ative bacteria, is a promising addition to the standard of 
care for patients with ABSSSI.
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